Clinical Trials Using Pneumococcal 13-valent Conjugate Vaccine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Pneumococcal 13-valent Conjugate Vaccine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Pneumococcal 13-Valent Conjugate Vaccine before and after CD19-Targeted CAR T Cell Immunotherapy for the Treatment of Relapsed or Refractory B Cell Lymphoma

    This phase II trial studies the side effects of pneumococcal 13-valent conjugate vaccine and how well it works when given before and after standard of care CD19-targeted chimeric antigen receptor (CAR) T cells therapy in treating patients with B cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Pneumococcal 13-valent conjugate vaccine may help to prevention of pneumococcal disease.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Vaccine Response With NT-I7

    Background: People with cancer, and especially older people, have a weakened immune system (the defense system of the body). This is often caused by the treatments for cancer. Older cancer survivors are therefore more prone to getting infections, some of which are preventable through vaccines. But because their immune systems are weakened, their response to vaccines is poor. Researchers want to see if a new drug, NT-I7, can help. Objective: To see if NT-I7 can boost the immune system. Eligibility: Adults 60 and older who have recently finished chemotherapy for breast, colorectal, or bladder cancer. Design: Participants will be screened with a physical exam, medical history, and blood and urine samples. Their heart s electrical activity will be checked. They will have an ultrasound of their spleen. They may give a tissue sample from a previous biopsy. Participants in phase 1a of the study will get 1 dose of NT-I7. It will be given by injection with a needle into the muscle of the upper arm, thigh, or buttocks. Participants in phase 1b will get 5 vaccines over a few months. They may get an optional booster and / or 6th vaccine. They will also get NT-I7. Participants will repeat the screening tests during the study. They may get a peripheral intravenous catheter in a vein in their hand or arm for blood draws. Participants may have apheresis. For this, blood is taken from an arm vein. The white blood cells are separated from the blood. The rest of the blood, minus the white blood cells, is returned into a vein in the other arm. A catheter may be used. Participants will have follow-up visits for 1 year.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer

    This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in treating patients with liver cancer that cannot be removed by surgery after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Giving autologous dendritic cells and Prevnar to patients with liver cancer after radiotherapy may help doctors determine if it is possible to stimulate the body's own immune system to fight against the tumor, and to see if this immune stimulation can be done safely.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Lenalidomide with or without an Allogeneic Myeloma Vaccine and Prevnar-13 in Treating Patients with Newly Diagnosed, Recurrent, or Refractory Multiple Myeloma

    This phase II trial studies how well lenalidomide with or without an allogeneic myeloma vaccine and prevnar-13 work in treating patients with multiple myeloma that is newly diagnosed, does not respond to treatment (refractory), or has come back (recurrent). Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines, such as an allogeneic myeloma vaccine and prevnar-13, may help the body build an effective immune response to kill cancer cells. Giving lenalidomide with an allogeneic myeloma vaccine and prevnar-13 may work better than lenalidomide alone in treating patients with multiple myeloma.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients with Non-Hodgkin Lymphoma

    This phase I / II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Influenza Vaccination in Preventing the Flu in Patients with Plasma Cell Disorders

    This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.
    Location: 2 locations